Top 20 BioPharma Companies based on 2020 Total Revenue

  • by
  • Despite having the global pandemic, the biopharma companies were involved in multiple M&A, licensing deals. The major focus of the year remains the production and distribution of vaccines to combat the COVID-19 globally
  • All the companies on our list are on the front line to combat this global crisis. The top 20 companies on the ledger changed from their 2019 ranking, leading to major ups & downs in the positions.
  • J&J remains at the top with a revenue of $82.50B, followed by Roche & Bayer with $65.95B & $50.62B as their revenue respectively. PharmaShots has compiled a list of the top 20 biopharma companies based on their 2020 total revenue

Total Revenue:  $13.44B

Pharma Segment Revenue: $13.44B

Founded Year:  1978

Market Cap:    $268.02B

Total Employees: ~ 9,100

Non-Pharma Segment Revenue: Nil

Headquarter: Massachusetts,United States

Stock Exchange: NASDAQ

Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. In Mar’ 2020, Biogen acquired BIIB118 (CK1 inhibitor) from Pfizer, while in Oct’2020 collaborated with Denali to co-develop & co-commercialize Denali’s LRRK2 inhibitors for PD.

Total Revenue:  $16.65B

Pharma Segment Revenue:    $16.65B

Founded Year: 1944

Market Cap:  $11.34B

Total Employees: ~40,216

Non-Pharma Segment Revenue: Nil

Headquarter: Petah Tikva, Israel

Stock Exchange: NYSE

Teva is a global pharmaceutical company that deals with g generics, specialty and over-the-counter products. In Jan’2020 and Mar’2020, the company launched Herzuma (trastuzumab-pkrb) which is biosimilar to Herceptin (trastuzumab), in Canada and the US, respectively.

Total Revenue:    $20.86B

Pharma Segment Revenue: $20.86B

Founded Year: 1989

Market Cap:  $69.25B

Total Employees: ~45,323

Non-Pharma Segment Revenue: Nil

Headquarter: Bagsværd, Denmark

Stock Exchange: Copenhagen

Novo Nordisk is a global healthcare company, headquartered in Denmark. The company is a leader in diabetes and obesity care and has a strong presence in other chronic diseases such as NASH, CV and AD. In 2020, Novo Nordisk’s Rybelsus got approved in the EU, the UK and Japan.

Total Revenue:  $21.44B

Pharma Segment Revenue:   $8.11B

Founded Year: 1800

Market Cap:   $173.48B

Total Employees: ~$58,000

Non-Pharma Segment Revenue: $13.33B

Headquarter: Darmstadt, Germany

Stock Exchange: ETR

The Merck Group, commonly known as Merck, is a German multinational science and technology company headquartered in Darmstadt. Its healthcare’s focus includes oncology, immuno-oncology, and neurology & immunology. In Jun’2019, the US FDA has approved IND for M5049 to treat Covid-19 pneumonia.

Total Revenue:   $23.92 B

Pharma Segment Revenue:   $17.62B

Founded Year:      1885

Market Cap:    Nil

Total Employees: ~ 52,000

Non-Pharma Segment Revenue: $6.3B

Headquarter: Ingelheim am Rhein, Germany

Stock Exchange: Nil

Boehringer Ingelheim is a research-driven biopharmaceutical company and has three core business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Boehringer Ingelheim reinforced its position in immune-oncology therapies by acquiring shares in the Northern Biologics, which was subsequently renamed BI IO Canada.

Total Revenue:    $24.53B

Pharma Segment Revenue:   $24.53B

Founded Year: 1901

Market Cap:   $182.32B

Total Employees: ~34,960

Non-Pharma Segment Revenue: Nil

Headquarter: Indiana, United States

Stock Exchange: NYSE

Eli Lilly is an American pharmaceutical company headquartered in Indianapolis, Indiana. The company discovers, develop, manufacture, and market products in a single business segment i.e human pharmaceutical products.  In 2020, Baricitinib was granted EUA for suspected or laboratory confirmed COVID-19, in combination with remdesivir, in hospitalized adults and pediatric patients.

Total Revenue:     $24.69B

Pharma Segment Revenue:     $24.69B

Founded Year: 1987

Market Cap:    $65.60B

Total Employees: ~ 13,600

Non-Pharma Segment Revenue: Nil

Headquarter: California, United States

Stock Exchange: NASDAQ

Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. In 2020, Gilead entered 18 partnerships and acquisitions to enhance its commercial portfolio and clinical pipeline across multiple therapeutic areas which include the acquisition of Immunomedics that added Trodelvy and other pipeline programs to our oncology portfolio.

Total Revenue:   $25.40B

Pharma Segment Revenue:    $25.40B

Founded Year: 1980

Market Cap:    $248.12B

Total Employees: ~ 22,000

Non-Pharma Segment Revenue: Nil

Headquarter: California, United States

Stock Exchange: NASDAQ

Amgen is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. In Dec’2020, the US FDA has approved d Riabni, a biosimilar to Rituxan (rituximab), for adult patients with NHL, CLL, granulomatosis with polyangiitis and microscopic polyangiitis and was launched in the US in Jan’2021.

Total Revenue:    $26.60B

Pharma Segment Revenue:      $26.60B

Founded Year:  1999

Market Cap:      $131.78B

Total Employees: ~76,100

Non-Pharma Segment Revenue: Nil

Headquarter: Cambridge, United Kingdom

Stock Exchange: NYSE

AstraZeneca is a global pharmaceutical focusing on Oncology; Cardiovascular, Renal & Metabolism and Respiratory & Immunology. In May’2020, AZ collaborated with RedX and got an exclusive global license to develop & commercialize RXC006 targeting fibrotic diseases including IPF.

Total Revenue:      $34.60B

Pharma Segment Revenue: $4.30B

Founded Year: 1900

Market Cap:      $120.11B

Total Employees: ~109,000

Non-Pharma Segment Revenue: $30.3B

Headquarter: Illinois, United States

Stock Exchange: NYSE

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Illinois. It has four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The products in the pharmaceutical segment include Creon, Duphaston, Lipanthyl, TriCor, Serc, etc.

Total Revenue:     $41.90B

Pharma Segment Revenue:   $41.90B

Founded Year: 1849

Market Cap:       $35.91B

Total Employees: ~ 1,01,200

Non-Pharma Segment Revenue: Nil

Headquarter: New York, United States

Stock Exchange: NYSE

Pfizer Inc. is a research-based, global biopharmaceutical company. In Apr’2020, it collaborated with BioNTech to develop, manufacture and commercialize an mRNA-based coronavirus vaccine program, BNT162, aimed at preventing COVID-19 while in Nov’2020, it spun off Upjohn Business with Mylan, which created a new global pharmaceutical company, Viatris.

Total Revenue:  $42.51B

Pharma Segment Revenue:         $42.51B

Founded Year: 1887

Market Cap:    $62.06B

Total Employees: ~30,250

Non-Pharma Segment Revenue: Nil

Headquarter: New York, United States

Stock Exchange: NYSE

Bristol-Myers Squibb (BMS) is an American pharmaceutical company focused on oncology, cardiovascular, immunology, and fibrosis. In Oct’2020, BMS obtained a global exclusive license to Dragonfly’s IL-12 investigational immunotherapy program, including its extended half-life cytokine DF6002. The company completed the acquisition of MyoKardia & Forbius in Nov & Sept’2020 respectively.

Total Revenue:    $44.07B

Pharma Revenue:      $30.19B

Founded Year: 1973

Market Cap:        $100.34B

Total Employees: ~ 99,412

Non-Pharma Segment Revenue: $13.88B

Headquarter: Paris, France

Stock Exchange: EPA

Sanofi is a global healthcare leader in vaccines providing healthcare solutions in 170+ countries around the world. In 2020, Sanofi entered into multiple agreements which include its collaboration with Kiadis Pharma, Kymera Therapeutics, Principia Biopharma and has completed the acquisition of Synthorx for $68/ share in cash, representing an aggregate equity value of ~$2.5B.

Total Revenue:     $45.80B

Pharma Segment Revenue:         $45.80B

Founded Year: 2012

Market Cap:    $105.21B

Total Employees: ~47,000

Non-Pharma Segment Revenue: Nil

Headquarter: Illinois, United States

Stock Exchange: NYSE

AbbVie is a global, research-based biopharmaceutical company that develops therapies majorly for chronic autoimmune diseases, oncology, virology with additional targets like cystic fibrosis and women’s health and has an enriched pipeline in immunology and neuroscience. The company completed Allergan’s acquisition which enhances its growth platform.

Total Revenue:   $46.59B

Pharma Segment Revenue:  $30.84B

Founded Year: 2000 

Market Cap:     $90.76B

Total Employees: ~ 94,066

Non-Pharma Segment Revenue: $15.75B

Headquarter: Brentford, United Kingdom

Stock Exchange: LON

GSK is a global healthcare company serving the world with drugs, vaccines & consumer healthcare products and is a leader in the areas of respiratory and HIV. In 2020, GSK collaborated with Sanofi to develop an adjuvanted COVID-19 vaccine and allied with VIR and Innovax to combat COVID-19.

Total Revenue:     $47.99B

Pharma Segment Revenue:   $43.02B

Founded Year: 1891

Market Cap:    $76.12B

Total Employees: 74,000

Non-Pharma Segment Revenue: $4.97B

Headquarter: NewJersey, United States

Stock Exchange: NYSE

Merck & Co. is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products. In Feb’2020, Merck announced its intention to spin-off products from its women’s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon & Co. (Organon) through distribution of Organon’s publicly traded stock to the company shareholders. The spin-off is expected to be completed late in the Q2’21.

Total Revenue:          $48.66B

Pharma Segment Revenue:   $48.66B

Founded Year: 1996

Market Cap:    $86.62B

Total Employees: ~105,794

Non-Pharma Segment Revenue: Nil

Headquarter: Basel, Switzerland

Stock Exchange: SIX Swiss Exchange, NYSE

Novartis is a multinational group of companies specializing in research, development, manufacturing, and marketing with a broad range of healthcare solutions including generic and ophthalmic therapies. In Nov’2020, Novartis has secured a global license to Mesoblast’s cell therapy remestemcel-L in the treatment of COVID-19 while its Tabrecta got FDA’s approval for NSCLC with METex14 in May’2020.

Total Revenue:   $50.62B

Pharma Segment Revenue:   $21.08B

Founded Year: 1863

Market Cap:      $63.33B

Total Employees: ~99,538

Non-Pharma Segment Revenue: $29.54B

Headquarter: Leverkusen, Germany

Stock Exchange: ETR

Bayer is a leading life science firm with three divisions pharmaceuticals, consumer health, and crop science. In Sept’2020, Bayer completed the acquisition of 100% of the shares in biotech company KaNDy, further expanding its development portfolio in women’s health while in Dec’2020, it acquired Asklepios BioPharmaceutical.

Total Revenue:    $65.95B

Pharma Segment Revenue:      $50.35B

Founded Year: 1896

Market Cap:      $346.12B

Total Employees: ~98,000

Non-Pharma Segment Revenue: $15.6B

Headquarter: Basel, Switzerland

Stock Exchange: SIX Swiss Exchange

Roche is a Swiss multinational healthcare company operating worldwide under pharmaceuticals and diagnostics divisions. In 2020, Roche initiated several approaches to fight against COVID-19. In Aug, Roche and Regeneron joined forces to develop, manufacture and distribute Regeneron’s Ab combination. In October, Roche and Atea collaborated to develop, manufacture, and distribute AT-527 targeting COVID-19 across the globe.

Total Revenue:     $82.50B

Pharma Segment Revenue:   $45.57B

Founded Year: 1887

Market Cap:   $163.61B

Total Employees: ~34,500

Non-Pharma Segment Revenue: $36.93B

Headquarter: New Jersey, United States

Stock Exchange: NYSE

Johnson & Johnson (J&J) is an American multinational healthcare company focused on the development and commercialization of pharmaceutical, medical device, and consumer packaged products. In Sept’2020, J&J begun a P-III study of its COVID-19 vaccines and has received $1B in Federal Vaccine Production Funding. Additionally, J&J acquired Momenta Pharmaceutical for $7.5B in Aug’2020.

Sources: Company annual reports, SEC filings, press releases, and company websites.

Market Cap source: Google finance (as on 8th April, 2021)

All revenues are reported in USD.

Note: Takeda is not included in the top 20 list, as its actual revenue is not available.

Related Post:

Top 20 BioPharma Companies based on 2019 Total Revenue

The post Top 20 BioPharma Companies based on 2020 Total Revenue first appeared on PharmaShots.